Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05543252 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Terminated
- Registry status
- Phase 2
- Development phase
- 428
- Enrollment target
NCT05543252 is a Phase 2 study that was terminated before completion, run by UCB Biopharma SRL. The registered enrollment target is 428 participants.
The verdict
NCT05543252, a Phase 2 study, was terminated before completion, sponsored by UCB Biopharma SRL.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 428 participants
- Enrollment target
Study Summary
The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
Interventions
- DRUG Minzasolmin (UCB0599)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2025-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05543252
The ClinicalTrials.gov registry entry for NCT05543252 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 428 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Minzasolmin (UCB0599) is the first listed.
NCT05543252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05543252 about?
NCT05543252 is a clinical study titled "An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease". The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
What is the current status of trial NCT05543252?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 428 participants. The study started on 2022-08-29. Estimated completion is 2025-03-25.
What interventions are being tested in trial NCT05543252?
The interventions under investigation include: Minzasolmin (UCB0599) (DRUG).
Who is sponsoring clinical trial NCT05543252?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.